Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rein Therapeutics ( (RNTX) ) has issued an update.
On June 24, 2025, Rein Therapeutics, Inc. announced the adjournment of its 2025 Annual Meeting of Stockholders to July 23, 2025, as a quorum was not achieved. This delay provides more time for stockholders to vote on proposals outlined in the company’s proxy statement.
The most recent analyst rating on (RNTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Average Trading Volume: 37,218
Technical Sentiment Signal: Sell
Current Market Cap: $34.12M
See more data about RNTX stock on TipRanks’ Stock Analysis page.